Stock Track | Hengrui Pharma Soars 36% in Hong Kong Debut After Oversubscribed IPO

Stock Track

May 23, 2025

Shares of Jiangsu Hengrui Pharmaceuticals Co. (01276.HK), China's largest drugmaker by market value, skyrocketed 36.32% in their Hong Kong stock market debut on Friday. The stellar performance came after the company raised HK$9.9 billion (US$1.3 billion) in a highly anticipated initial public offering (IPO).

The strong debut was fueled by overwhelming investor demand. Hengrui's Hong Kong public offering was oversubscribed by an impressive 454.85 times, while the international offering saw 17.09 times oversubscription. The company priced its shares at HK$44.05, the top end of the marketed range, and opened trading at HK$57 before climbing to HK$60, reflecting robust investor confidence in the pharmaceutical giant.

Founded in 1970, Hengrui Pharmaceuticals has evolved from a small factory producing pharmaceutical ingredients to a leader in China's rapidly emerging biotech sector. The company plans to use the IPO proceeds to expand its research into treatments for cancer, cardiometabolic diseases, and neurological disorders. With a dozen international development deals and a landmark pact valued at up to US$6 billion for experimental obesity drugs, Hengrui is positioning itself for growth both domestically and globally, although it has yet to win approval for its branded drugs outside of China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1125632370"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125632370\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125632370?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125632370","market":"nz","top_or_hot":-1,"title":"Stock Track | Hengrui Pharma Soars 36% in Hong Kong Debut After Oversubscribed IPO","media":"Stock Track","content":"<p>Shares of Jiangsu Hengrui Pharmaceuticals Co. (01276.HK), China's largest drugmaker by market value, skyrocketed 36.32% in their Hong Kong stock market debut on Friday. The stellar performance came after the company raised HK$9.9 billion (US$1.3 billion) in a highly anticipated initial public offering (IPO).</p>\n\n<p>The strong debut was fueled by overwhelming investor demand. Hengrui's Hong Kong public offering was oversubscribed by an impressive 454.85 times, while the international offering saw 17.09 times oversubscription. The company priced its shares at HK$44.05, the top end of the marketed range, and opened trading at HK$57 before climbing to HK$60, reflecting robust investor confidence in the pharmaceutical giant.</p>\n\n<p>Founded in 1970, Hengrui Pharmaceuticals has evolved from a small factory producing pharmaceutical ingredients to a leader in China's rapidly emerging biotech sector. The company plans to use the IPO proceeds to expand its research into treatments for cancer, cardiometabolic diseases, and neurological disorders. With a dozen international development deals and a landmark pact valued at up to US$6 billion for experimental obesity drugs, Hengrui is positioning itself for growth both domestically and globally, although it has yet to win approval for its branded drugs outside of China.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hengrui Pharma Soars 36% in Hong Kong Debut After Oversubscribed IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hengrui Pharma Soars 36% in Hong Kong Debut After Oversubscribed IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-23 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Jiangsu Hengrui Pharmaceuticals Co. (01276.HK), China's largest drugmaker by market value, skyrocketed 36.32% in their Hong Kong stock market debut on Friday. The stellar performance came after the company raised HK$9.9 billion (US$1.3 billion) in a highly anticipated initial public offering (IPO).</p>\n\n<p>The strong debut was fueled by overwhelming investor demand. Hengrui's Hong Kong public offering was oversubscribed by an impressive 454.85 times, while the international offering saw 17.09 times oversubscription. The company priced its shares at HK$44.05, the top end of the marketed range, and opened trading at HK$57 before climbing to HK$60, reflecting robust investor confidence in the pharmaceutical giant.</p>\n\n<p>Founded in 1970, Hengrui Pharmaceuticals has evolved from a small factory producing pharmaceutical ingredients to a leader in China's rapidly emerging biotech sector. The company plans to use the IPO proceeds to expand its research into treatments for cancer, cardiometabolic diseases, and neurological disorders. With a dozen international development deals and a landmark pact valued at up to US$6 billion for experimental obesity drugs, Hengrui is positioning itself for growth both domestically and globally, although it has yet to win approval for its branded drugs outside of China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1125632370","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125632370","pubTimestamp":1747964011,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Jiangsu Hengrui Pharmaceuticals Co. , China's largest drugmaker by market value, skyrocketed 36.32% in their Hong Kong stock market debut on Friday. The stellar performance came after the company raised HK$9.9 billion  in a highly anticipated initial public offering .The strong debut was fueled by overwhelming investor demand. Hengrui's Hong Kong public offering was oversubscribed by an impressive 454.85 times, while the international offering saw 17.09 times oversubscription. The comp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"股票赛道恒瑞医药IPO超额认购后在香港上市飙升36%","themeId":"92258637d6ff1e9cb4f4844790de8572","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"Shares of Jiangsu Hengrui Pharmaceuticals Co. (01276.HK), China's largest drugmaker by market value, skyrocketed 36.32% in their Hong Kong stock market debut on Friday. The stellar performance came after the company raised HK$9.9 billion (US$1.3 billion) in a highly anticipated initial public offering (IPO).\nThe strong debut was fueled by overwhelming investor demand. Hengrui's Hong Kong public offering was oversubscribed by an impressive 454.85 times, while the international offering saw 17.09 times oversubscription. The company priced its shares at HK$44.05, the top end of the marketed range, and opened trading at HK$57 before climbing to HK$60, reflecting robust investor confidence in the pharmaceutical giant.\nFounded in 1970, Hengrui Pharmaceuticals has evolved from a small factory producing pharmaceutical ingredients to a leader in China's rapidly emerging biotech sector. The company plans to use the IPO proceeds to expand its research into treatments for cancer, cardiometabolic diseases, and neurological disorders. With a dozen international development deals and a landmark pact valued at up to US$6 billion for experimental obesity drugs, Hengrui is positioning itself for growth both domestically and globally, although it has yet to win approval for its branded drugs outside of China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}